

DOCTORAL THESIS

Neuroprotective effects of a novel TFEB activator E4 and its self-carried nanoparticles in MPTP-induced Parkinson's disease models

Wang, Ziyang

Date of Award:
2019

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

ABSTRACT

Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized by cell death in the substantia nigra pars compacta (SNpc) and the appearance of aggregated α -synuclein (α -syn). Autophagosomes accumulation and lysosomal reduction were discovered in PD patients' brain, which indicated the deficiency of autophagy in the progress of PD.

TFEB (transcription factor EB) is a member of basic helix –loop-helix-leucine-zipper transcription factors (MiT family) and is a key master monitor for autophagy and lysosome biogenesis. Overexpression of TFEB is able to rescue the dopaminergic neurons (DAs) loss and α -syn aggregated in α -syn transgenic mice model and MPTP PD model. Hence, in recent years, many researchers have considered TFEB as a new therapeutic target for PD

In this study, we discovered a novel TFEB activator named E4 by screening synthesized curcumin analogs. We have found that E4 strongly promoted TFEB nuclear translocation and induced autophagy in different cell lines. TFEB is essential for E4-induced autophagy flux. We also demonstrated that the underlying mechanism of E4 activate TFEB is mainly through inhibiting mTORC1 activity . We constitutively activate mTOR by knockdown TSC2 abrogated the increase of LC3-II and decrease of p-TFEB.

We further estimated the protective effects of E4 in overexpressed α -syn model and neurotoxins induced cytotoxicity model. Treated with E4 for 48h in N2a transfected with A53T α -synuclein cells dose-dependently reduce the α -synuclein level. At the same time, we established the MPP⁺ model in PC12 cells which is pre-treated cell with E4 for 6 hours and then co-treated cells with MPP⁺ for 48 hours. The cell viability results showed that E4 significantly protect PC12 cells against MPP⁺ cytotoxicity dose-dependently. E4 had shown good neuroprotective effects in PD *in vitro* models while poor water solubility and low brain permeability restricted its application in PD animal models.

Hence, assembling E4 molecules into self-carried nanoparticles (NanoE4) addressed the issue of poor water solubility and intranasal administration solved the problem of low permeability. In order to track NanoE4 release *in vitro* and *in vivo*, we further investigated the absorption and emission of NanoE4. However, the absorption fluorescence results showed that NanoE4 exhibits the strong aggregation-caused quenching effect (ACQ) due to π - π stacking of the planar molecule within the NPs. NanoE4 have much weak emission compared with E4 molecules. Therefore, we fabricated E4-TPAAQ NPs by co-precipitating E4 molecules with the reported fluorescent organic compound TPAAQ (2,6-Bis[4-(diphenylamino) phenyl] anthraquinone).

Next, we developed an intranasal drug delivery system in our lab. After intranasal

co-drop nanodrug E4-TPAAQ NPs for 24 hours, we observed strong fluorescence distributed in the brain which indicated that deliver nanoparticles into the brain successfully through nasal-brain system. Therefore, we examined the protective effect of NanoE4 in MPTP-induced PD mice model. In MPTP models, we found autophagy dysfunction, motor function decrease and increase of α -synuclein as reported previously. Treatment with NanoE4 rescued the motor dysfunction induced by MPTP. NanoE4 also increase TH level in the striatum part of midbrain. NanoE4 treatment also decreased the α -synuclein protein aggregate in both SNpc and striatum. Overall, these results demonstrate the neuroprotection NanoE4 against PD.

Collectively, our findings 1) discovered a novel TFEB activator E4 that inhibited the mTOR pathway 2) indicated *in vitro* and *in vivo* experimental evidence for TFEB activator as the anti-PD drug candidate 3) provide a novel drug develop and delivery system for potential PD that limited by water solubility and BBB (blood-brain barrier) obstacle.

KEYWORDS: TFEB; MPP⁺/MPTP; self-carried nanoparticles; intranasal; Parkinson's disease; curcumin

TABLE OF CONTENTS

DECLARATION.....	i
ABSTRACT.....	ii
ACKNOWLEDGEMENTS	v
TABLE OF CONTENTS.....	vii
LIST OF TABLES.....	xiii
LIST OF FIGURES	xiv
LIST OF ABBREVIATION	xx
CHAPTER 1.....	1
INTRODUCTION	1
1.1 PARKINSON’S DISEASE.....	2
1.2 EPIDEMIOLOGY OF PD	3
1.3 NEUROPATHOLOGY OF PD	4
1.4 ETIOLOGY OF PD.....	6
1.4.1 <i>Environmental risk factor</i>	6
1.4.2 <i>Gene mutant of PD</i>	7
1.4.3 <i>Autophagy-lysosome pathway (ALP) and PD</i>	10
1.4.4 <i>TFEB is the new therapeutic target for PD</i>	13
1.5 MPP ⁺ /MPTP-INDUCED PD MODEL.....	15

1.6	SELF-CARRIED NANOPARTICLE AND INTRANASAL DRUG DELIVERY ...	16
1.6.1	<i>The Self-carried Nanoparticles</i>.....	16
1.6.1	<i>Intranasal administration and BBB</i>	18
1.7	TREATMENT FOR PD.	19
CHAPTER 2	22
HYPOTHESIS AND OBJECTIVES	22
CHAPTER 3	26
CURCUMIN ANALOG E4 PROMOTED TFEB NUCLEAR TRANSLOCATION, INDUCED AUTOPHAGY FLUX, AND LYSOSOME BIOGENESIS	26
3.1	INTRODUCTION.....	27
3.2	RESEARCH MATERIALS AND METHODOLOGY	28
3.2.1	<i>Reagents and antibodies</i>.....	28
3.2.2	<i>Cell culture</i>	29
3.2.3	<i>RNA interference assay</i>.....	29
3.2.4	<i>Transfection of plasmids into N2a cells</i>	30
3.2.5	<i>Immunostaining</i>	31
3.2.6	<i>Western blotting analysis</i>.....	31
3.2.7	<i>Isolation of the cytosol and the nucleus fractions</i>.....	32
3.2.8	<i>Statistical analysis</i>	33
3.3	RESULTS.....	34

3.3.1	<i>E4 promoted TFEB activation in different cell lines</i>	34
3.3.2	<i>E4 induced autophagy flux in N2a cells</i>	38
3.3.3	<i>E4 increased lysosome biogenesis and activities</i>	43
3.3.4	<i>TFEB activation is required for E4-induced autophagy and lysosome biogenesis</i>	46
3.4	DISCUSSION	52
CHAPTER 4.....		55
E4 PROMOTED TFEB TRANSLOCATION AND INDUCED AUTOPHAGY THROUGH MTOR INHIBITION		55
4.1	INTRODUCTION.....	56
4.2	MATERIAL AND METHODS	57
4.2.1	<i>Reagents and antibodies</i>	57
4.2.2	<i>RNA interference assay</i>	58
4.2.3	<i>Transfection of plasmids into N2a cells</i>	59
4.2.4	<i>Immunostaining</i>	59
4.2.5	<i>Western blotting analysis</i>	60
4.2.6	<i>Alamar blue assay</i>	61
4.2.7	<i>Statistical analysis</i>	61
4.3	RESULTS.....	62
4.3.1	<i>E4 inhibited AKT/mTOR activity in a dose dependent manner and inhibited p70S6K/ mTOR in a time dependent manner</i>	62
4.3.2	<i>E4 abrogate the LAMP1 and mTOR colocalization and decrease p-</i>	

<i>TFEB (ser 142)</i>	65
<i>4.3.3 Constitutively activated mTOR by knock down TSC2 could interrupt the autophagy flux and TFEB dephosphorylation</i>	66
<i>4.3.4 E4 promoted the α-synuclein degradation and protected neuronal cells against MPP⁺ neurotoxicity</i>	68
4.4 DISCUSSION	71
CHAPTER 5	74
SELF-CARRIED NANOPARTICLES OF E4	74
5.1 INTRODUCTION	75
5.2 MATERIAL AND METHODS	76
<i>5.2.1 Reagents and antibodies</i>	76
<i>5.2.2 Preparation of the E4 pure nanodrugs (NanoE4) and dye-doped E4 nanodrugs (E4-TPAAQ NPs)</i>	76
<i>5.2.3 Characterization of NanoE4 and E4-TPAAQ NPs</i>	77
<i>5.2.4 Immunostaining</i>	77
<i>5.2.5 Western blotting</i>	78
<i>5.2.6 Alamar blue assay</i>	78
<i>5.2.7 Statistical analysis</i>	78
5.3 RESULTS	80
<i>5.3.1 Characterization of E4 self-carried nanoparticles</i>	80
<i>5.3.2 Characterization of E4-TPAAQ self-carried nanoparticles</i>	83
<i>5.3.3 E4 self-carried nanoparticles promote TFEB nuclear translocation</i>	

<i>and induce autophagy flux</i>	89
5.3.4 <i>E4 self-assembly nanoparticles protected neuronal cells in different PD cell experimental models</i>	94
5.4 DISCUSSION	96
CHAPTER 6.....	99
NEUROPROTECTIVE EFFECT OF NANO E4 IN MPTP-INDUCED PD ANIMAL MODEL	99
6.1 INTRODUCTION.....	100
6.2 MATERIAL AND METHODS	102
6.2.1 <i>Reagents</i>	102
6.2.2 <i>Animals</i>	102
6.2.3 <i>Open Field Test</i>	103
6.2.4 <i>Rotarod test</i>	103
6.2.5 <i>In Vivo imaging of tissue distribution studies</i>	104
6.2.6 <i>Perfusion and tissue processing</i>	104
6.2.7 <i>TH staining for brain sections</i>	105
6.2.8 <i>Immunostaining for brain sections</i>	105
6.2.9 <i>Western blotting</i>	106
6.2.10 <i>Statistical analysis</i>	106
6.3 RESULTS.....	107
6.3.1 <i>Established the MPTP–induced PD mice model</i>	107
6.3.2 <i>E4 NPs intranasal administration help E4 NPs bypass the Brain</i>	

<i>blood barrier</i>	108
6.3.3 E4 NPs treatment mitigated motor dysfunction in MPTP mice model	110
6.3.4 Nasal E4 NPs in MPTP PD models restored LC3-II decrease and increase TH level	113
6.3.5 E4 NPs decrease the α-synuclein aggregate in MPTP mice model.	118
6.4 DISCUSSION	121
CHAPTER 7	124
GENERAL DISCUSSION AND CONCLUSIONS	124
7.1 IDENTIFY NOVEL TFEB ACTIVATOR VIA MTOR INHIBITION	125
7.2 MODIFIED INTRANASAL ROUTE COMBINED WITH SELF-CARRIED NANOPARTICLES IS A NEW DRUG DELIVERY SYSTEM FOR TREATING PD	125
7.3 EVALUATE THE NEUROPROTECTIVE EFFECT OF TFEB ACTIVATOR E4 IN PD EXPERIMENTAL MODELS	127
7.4 LIMITATION AND FURTHER WORK	128
REFERENCE	130
PUBLICATIONS LIST	159
ABSTRACTS PRESENTED AT INTERNATIONAL CONFERENCES: ...	160
CURRICULUM VITAE	164